Navigation Links
The Atherothrombotic Diseases Market Will Increase from $36 Billion in 2012 to $47 Billion in 2022
Date:12/19/2013

BURLINGTON, Mass., Dec. 19, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the launch of numerous add-on therapies in the atherothrombotic diseases market (incorporating pharmacotherapies for the treatment of coronary heart disease, peripheral arterial disease and ischemic stroke and transient ischemic attack) will drive the market to increase from $36 billion in 2012 to $47 billion in 2022. The launch of several premium-priced add-on therapies will offset the generic erosion of key brands and drive significant market growth during the second half of the study period (2017-2022).

(Logo: http://photos.prnewswire.com/prnh/20130103/MM36784LOGO )

The much-anticipated arrival of two antidyslipidemic drug classes, the cholesteryl ester transfer protein (CETP) inhibitors and the proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, is expected to begin in 2017, with the launch of Eli Lilly's CETP inhibitor evacetrapib. With morbidity and mortality data available at launch, Decision Resources expects rapid uptake of these agents as add-on therapies, particularly in high-risk patients, significantly contributing to market growth from 2017 to 2022.

"Interviewed thought leaders are very excited about the potential of the emerging PCSK9 inhibitor drug class," said Decision Resources Senior Director Conor Walsh, Ph.D. "The clinical profile from Phase II data has been promising, combining strong reductions in LDL-C on top of statin therapy with an apparently good safety and tolerability profile. Although their injectable nature and anticipated high price will limit widespread use, we believe blockbuster status is achievable."

The Pharmacor advisory service report entitled Atherothrombotic Diseases, which will be published in the days ahead, finds that despite reductions in risk due to improved public health measures and primary prophylaxis, the number of diagnosed prevalent cases of atherothrombotic disease will rise steadily during the forecast period, driven by improvements in post-acute coronary syndrome and post-stroke survival, a greater proportion of cases being diagnosed and aging populations. This rise, along with the launch of high-priced add-on therapies, will boost the value of the atherothrombotic diseases market.

The report also finds that the overall value of the antithrombotic agent market will benefit from the expansion of current, premium-priced, oral antithrombotic agents, such as AstraZeneca's Brilinta/Brilique and Bayer/Janssen's Xarelto, into new indications, further eroding the dominance of clopidogrel (Bristol-Myers Squibb/Sanofi's Plavix/Iscover, generics). Further support will come from the launch of Merck's vorapaxar for the treatment of post-myocardial infarction patients.

About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.


'/>"/>
SOURCE Decision Resources
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. High Cost of Biologics and Novel Oral Agents to Treat Immune Diseases Limits Patient Access
2. Lumena Pharmaceuticals Receives Positive Opinion for Orphan Drug Designation in the European Union for LUM001 in Four Rare Liver Diseases
3. Alzheimers Drug Discovery Foundation Expands its ADDF ACCESS Program to Improve Quality and Efficiency of Drug Research for Neurodegenerative Diseases
4. Rheumatology Network Presents Latest Advances Against Baffling Inflammatory Diseases From Major Rheumatology Conference
5. Harrisvaccines, Inc. Secures Exclusive Rights From AlphaVax, Inc. to Develop RNA Particle Vaccines for All Diseases in Companion Animals
6. Simeprevir Data in Hepatitis C Patients to be Presented at the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)
7. Warnings for Hepatitis B Reactivation in Cancer Patients Welcomed by the American Association for the Study of Liver Diseases
8. Gliknik Enters Into Licensing Agreement With Pfizer For Drug Candidate Targeting Autoimmune Diseases
9. Lumena Pharmaceuticals Receives Orphan Drug Designation from US Food & Drug Administration for LUM001 in Four Rare Liver Diseases
10. Edison Pharmaceuticals Announces Initiation of NIH-Sponsored EPI-743 Clinical Trial with NIH Undiagnosed Diseases Program Patients
11. Aptel Research Launches Unique Patient-centric Syndicated Report Series That Analyze the Patient Journey for Chronic Diseases in Specialty Markets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/4/2017)... 4, 2017  According to the Centers for Disease Control and Prevention ... . PhysicianOne Urgent Care is helping communities across Massachusetts ... , by offering no-cost* flu shots through the end of the month. ... health insurance regulations. ... to get a flu shot is by the end of October, according ...
(Date:10/2/2017)... , Oct. 2, 2017  AllianceRx Walgreens Prime, the ... by Walgreens and pharmacy benefit manager Prime Therapeutics LLC ... brand, which included the unveiling of new signage at ... as well as at a few other company-owned facilities ... brand to patients, some of whom will begin to ...
(Date:9/28/2017)... , Sept. 28, 2017 Cohen Veterans ... advance the use of wearable and home sensors for ... disorders. Early Signal Foundation, a nonprofit organization focused on ... will provide an affordable analytical system to record and ... ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... As health professionals work to improve their ... The patient is doing more than filling out a survey; in many cases health ... increasing emphasis in health care and research on the importance of active engagement with ...
(Date:10/13/2017)... Ky. (PRWEB) , ... October 13, 2017 , ... The ... MPH to become its next President and Chief Executive Officer, succeeding Dr. James C. ... CEO Elect beginning July 1, 2018 until Dr. Puffer’s retirement at the end of ...
(Date:10/13/2017)... Las Vegas, Nevada (PRWEB) , ... October 13, 2017 , ... ... of 7® Hemp CBD Oil utilizing Purzorb™ technology. Applying the Purzorb™process to full spectrum ... CBD dose required and providing a CBD form that can be easily incorporated into ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... Lori R. ... a member of ElderCounsel, a national organization of elder law and special needs planning ... laws and rules. It also provides a forum to network with elder law attorneys ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... Many families ... However, many long-term care insurance companies have a waiver for care if the client ... elimination period, when the family pays for care, is often waived, so the benefits ...
Breaking Medicine News(10 mins):